320MO Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: A randomized, multicenter, phase III trial
L. Zhang, Weizhen Fang, J. Min, Nan Yang, Qiang Yu, Yufeng Cheng, Yuxiao Zhao, M. Li, Heyi Chen, Shuai Ren, J. Zhou, Wenyi Zhuang, Xiangling Qin, L. Cao, Y. Yu, J. Zhang, Jing He, Jianheng Feng, H. Yu
Topics & Concepts
CrizotinibMedicineInternal medicineOncologyRandomized controlled trialLung cancerMalignant pleural effusionLung Cancer Treatments and MutationsCancer therapeutics and mechanismsLung Cancer Research Studies